Establishment of parallel workflows vital to gain
regulatory approvals for the use of artificial intelligence
capabilities in digital pathology, finds Frost &
Sullivan
SANTA CLARA, Calif.,
Feb. 25, 2019 /PRNewswire/
-- Over the next decade, there will be a shift in digital
pathology and artificial intelligence (AI)
applications from the pharmaceutical sector to clinical
diagnostics. Once they are established as primary and secondary
diagnostic tools, clinicians will be able to decrease turnaround
time, prioritize critical cases, and improve overall patient
outcomes. However, for AI tools to gain regulatory approval for
primary diagnosis in digital pathology, it is imperative to adopt a
parallel workflow to showcase the superior benefits of
pathology diagnoses that amass data.
"AI has the potential to analyze big data and find
patterns and insights that could enhance patient outcomes in the
field of pathology," said Deepak
Jayakumar, Senior Research Analyst, TechVision.
"It can serve as a supplementary or a validation tool in imaging
analytics for pathologists and help process more slides in a
shorter duration. So far, AI-based medical diagnostic tools like
OsteoDetect have already been approved for use by the
FDA for the detection of distal radius fracture.
Furthermore, AI-powered tools can better identify skin
lesions and the presence of invasive breast cancer."
Frost & Sullivan's recent analysis, Digital Pathology:
Roadmap to the Future of Medical Diagnosis, covers the
solutions of digital whole slide scanning, digital
imaging solutions, and digital data repository. The
study identifies technology advancements, applications, and
potential, as well as presents the most successful business models
and strategies currently dominating the market.
For further information on this analysis,
please visit: http://frost.ly/37w
"Hospitals and diagnostic labs will be the largest adopters of
digital pathology over the next decade," noted Jayakumar.
"Technology innovators can ensure greater commercialization by
focusing on improving cost optimization for end users through
pay-per-use or Software-as-a-Service (SaaS)
models. Additionally, they could map service gaps, expand product
portfolios, and use the information obtained from clinical data to
develop cutting-edge solutions."
A few highlighted growth opportunities for digital
pathology-enabling technology companies within this analysis
include:
- Responsible use of datasets owned by medical institutions. A
case in point is the creation of an imaging research warehouse by
Mount Sinai Health System, which equips researchers with
imaging and clinical data of more than a million patients.
- Collaboration with hospitals, diagnostic labs, and medical
institutes to generate datasets comparing digital pathology and
traditional methods to present a solid case for the regulatory
approval of their product.
- Approval of AI-based tools needs to be a top priority for
AI-based, digital pathology-focused companies as low-to-medium risk
diagnostic avenues are an innovative way to transition from
pharmaceutical to mainstream clinical applications in the digital
pathology segment.
Digital Pathology: Roadmap to the Future of Medical
Diagnosis is part of Frost & Sullivan's global Medical
Devices & Imaging Growth Partnership Service program.
Frost & Sullivan's global TechVision practice is focused on
innovation, disruption and convergence and provides a variety of
technology-based newsletters and research services as well as
growth consulting services. Its premier offering, the Top 50
Technologies program, identifies and evaluates the most valuable
emerging and disruptive technologies enabling products with
near-term potential. A unique feature of the TechVision program is
an annual selection of 50 technologies that can generate
convergence scenarios, possibly disrupt existing business models,
and drive transformational growth. View a summary of our TechVision
program by clicking on the following link:
http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
For over five decades, Frost & Sullivan has become
world-renowned for its role in helping investors, corporate leaders
and governments navigate economic changes and identify disruptive
technologies, Mega Trends, new business models and companies to
action, resulting in a continuous flow of growth opportunities to
drive future success. Contact us: Start the discussion.
Digital Pathology: Roadmap to the Future of
Medical Diagnosis
D888-TV
Contact:
Mariana
Fernandez
T: +1 210 348 10 12
T: +54 11 4778 3540
E: Mariana.Fernandez@frost.com
http://ww2.frost.com
http://www.frost.com/techvision
View original content to download
multimedia:http://www.prnewswire.com/news-releases/top-3-growth-opportunities-for-digital-pathology-enabling-technology-companies-300801406.html
SOURCE Frost & Sullivan